eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Treatment of children with all stages of hepatoblastoma

eagle-i ID


Resource Type

  1. Clinical trial


  1. Intervention
  2. Intervention
  3. Intervention
  4. Intervention
  5. Intervention
  6. Additional Topic(s)
    Antineoplastic combined chemotherapy protocols
  7. Additional Topic(s)
  8. Resource Description
    In this study, the risk level for the disease coming back after treatment is either very low, low, intermediate or high. Subjects are treated according to the risk group they are in. Other questions that researchers want to answer in this study are: Can a rating system called Pretreatment Extent of Disease (or PRETEXT) be used to decide if a tumor can be removed by surgery? Also, do different doctors give the same or different PRETEXT ratings when looking at the same patient’s tumor on a scan? Are there other factors that are present in children with hepatoblastoma that can be used to develop better treatments? For low-risk hepatoblastoma: Is it possible to give only 2 cycles of Cisplatin, 5-Fluorouracil and Vincristine, also called C5V (instead of the standard 4 cycles) in addition to taking out the tumor with surgery and still have good treatment success rates? For intermediate-risk hepatoblastoma: Can doxorubicin (chemotherapy) be given with C5V without causing too many side effects? For intermediate-risk and high-risk hepatoblastoma: Is it possible for subjects to be referred by their doctor to a center with experts in liver transplant surgery by the end of 2 cycles of chemotherapy? And is it then possible for these subjects to have their liver transplant done at the end of 4 cycles of chemotherapy? For high-risk hepatoblastoma: Are vincristine and irinotecan (types of chemotherapy) useful chemotherapy drugs for treating high-risk hepatoblastoma?
  9. Contact
    Berenberg, Jeffrey
  10. PI
    Wilkinson, Robert, M.D.
  11. Topic
  12. Study Population
    Persons 21 years or younger with any stage of newly diagnosed hepatoblastoma. Subjects previously treated with any kind of chemotherapy or other cancer therapy are not eligible for this study.
  13. Funded by
    Children's Oncology Group
  14. Phase
    Phase 3 clinical trial
  15. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016